MannKind Corporation (MNKD) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Mankind Corporation first quarter 2025 financial results earnings call. As a reminder, this call is being recorded on May 8th, 2025 and will be available for playback on the Mankind Corporation website shortly after the conclusion of this call and available for approximately 90 days. This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainty, which can cause actual risks to differ materially from the stated expectations. For further information on the company's risk factors, Please see the form 10Q for the quarterly period ended March 31st, 2025 on file with the SEC, the earnings release and the slides prepared for this presentation. Joining us today for Mankind are Chief Executive Officer Michael Castagna and the Chief Financial Officer Chris Prentice. I'd now like to turn the conference over to Mr Castagna. Please go ahead, sir. Thank you, everyone, for joining us this morning. Today, joining me is Chris Prentice, our Chief Financial Officer. We'll be going through operational pipeline highlights, our financial review, and some of my remarks at the end. As we've engaged with the investment community over the last several months, our discussions highlight that investors, especially in these uncertain times, are seeking commercial stage companies that have a profile of growing revenue, promising pipeline, and a strong financial position combined with very little debt that we have going forward. I'm proud to share that this depicts where mankind is today and are excited by our five key pillars of growth above. Now I'm going to highlight our Q1 2025 key points. Our endocrine business grew 20% on NRXs and 14% on TRXs. We have filed for a label change for our adult, which is a 2X...